To the Editor In their Research Letter published in JAMA Oncology, Fleury et al1 suggest that patients with cancer will be less likely to consider trial participation even when sites return to prepandemic status. Nevertheless, we would like to point out that this conclusion should be interpreted cautiously because this study has several limitations, and mechanistic factors to support these findings are missing.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Bayle A, Barlesi F, Massard C. Patient Willingness to Enroll in Cancer Clinical Trials When Sites Return to Prepandemic Status. JAMA Oncol. 2021;7(6):939–940. doi:10.1001/jamaoncol.2021.0376
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.